Do SGLT-2 inhibitors help reduce heart failure hospitalization for acute coronary syndrome?
SGLT-2 inhibitors are a class of medications originally developed for diabetes that have shown benefits for heart and kidney health. For patients who have had an acute coronary syndrome (ACS) — a heart attack or unstable angina — there is growing evidence that these drugs can help prevent future heart failure events. A 2024 meta-analysis specifically looked at this question and found a clear reduction in hospitalizations for heart failure when SGLT-2 inhibitors were started after ACS.
What the research says
A 2024 meta-analysis of 10 studies (7 randomized trials and 3 observational studies) including over 15,000 patients found that SGLT-2 inhibitors significantly reduced the risk of first heart failure hospitalization by 22% (RR = 0.78, 95% CI 0.66–0.92) in patients with ACS who had at least one additional risk factor for heart failure 1. The same analysis also showed a reduction in stroke (RR = 0.56) and cardiac death (RR = 0.84), though the cardiac death finding was driven mainly by observational studies 1. These results had low statistical heterogeneity, meaning the findings were consistent across studies 1.
Other research supports the broader cardiovascular benefits of SGLT-2 inhibitors. A large collaborative meta-analysis of 11 trials involving nearly 79,000 patients across different populations (diabetes, heart failure, chronic kidney disease) confirmed that SGLT-2 inhibitors reduce the risk of major adverse cardiovascular events, including heart failure hospitalization 10. In older or frail patients with type 2 diabetes and heart failure, SGLT-2 inhibitors were associated with a 31% reduction in hospitalization for heart failure (RR 0.69, 95% CI 0.59–0.81) 9. Additionally, a 2025 review highlighted that SGLT-2 inhibitors may protect the heart through multiple mechanisms, such as improving endothelial function, reducing inflammation, and limiting damage from ischemia-reperfusion injury, which is relevant after ACS 11.
While the primary evidence comes from the 2024 ACS-specific meta-analysis 1, the consistency of findings across different patient groups and the plausible biological mechanisms strengthen the case that SGLT-2 inhibitors are beneficial for reducing heart failure hospitalization after ACS.
What to ask your doctor
- Based on my recent acute coronary syndrome, could an SGLT-2 inhibitor be appropriate for me to help prevent heart failure?
- What are the potential side effects of SGLT-2 inhibitors, such as urinary tract infections or diabetic ketoacidosis, and how would we monitor for them?
- Do I have any additional risk factors (like diabetes, kidney disease, or prior heart failure) that would make me a good candidate for this treatment?
- How soon after my ACS event should I consider starting an SGLT-2 inhibitor, and would it interact with my current medications?
- Are there any other medications or lifestyle changes that could further reduce my risk of heart failure hospitalization?
This question is drawn from common patient questions about Cardiology and answered using cited medical research. We do not provide individualized advice.